See more : Nykredit Invest Globale Fokusaktier KL (NYIGLA.CO) Income Statement Analysis – Financial Results
Complete financial analysis of electroCore, Inc. (ECOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of electroCore, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Asseco South Eastern Europe S.A. (ASE.WA) Income Statement Analysis – Financial Results
- Get Nice Holdings Limited (0064.HK) Income Statement Analysis – Financial Results
- Orange S.A. (FTE.DE) Income Statement Analysis – Financial Results
- Homeland Security Corporation (HSCC) Income Statement Analysis – Financial Results
- Tix Corporation (TIXC) Income Statement Analysis – Financial Results
electroCore, Inc. (ECOR)
About electroCore, Inc.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16.03M | 8.59M | 5.45M | 3.50M | 2.39M | 992.95K | 811.46K | 254.14K |
| Cost of Revenue | 2.80M | 1.62M | 1.39M | 1.74M | 1.16M | 578.74K | 518.53K | 123.73K |
| Gross Profit | 13.23M | 6.98M | 4.07M | 1.76M | 1.23M | 414.21K | 292.93K | 130.41K |
| Gross Profit Ratio | 82.51% | 81.19% | 74.59% | 50.30% | 51.59% | 41.71% | 36.10% | 51.31% |
| Research & Development | 5.32M | 5.52M | 2.54M | 4.20M | 9.90M | 12.47M | 7.83M | 7.97M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 42.50M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 26.71M | 24.33M | 21.57M | 21.84M | 35.42M | 42.50M | 18.11M | 7.17M |
| Other Expenses | 0.00 | -6.00K | -8.30K | -17.80K | -12.00K | -344.91K | -4.89K | 7.17M |
| Operating Expenses | 32.03M | 29.85M | 24.11M | 26.04M | 45.32M | 54.97M | 25.94M | 15.14M |
| Cost & Expenses | 34.84M | 31.47M | 25.49M | 27.78M | 46.48M | 55.55M | 26.46M | 15.26M |
| Interest Income | 433.00K | 287.00K | 10.70K | 84.30K | 970.59K | 1.01M | 99.03K | 0.00 |
| Interest Expense | 0.00 | 287.00K | 0.00 | 8.34K | 0.00 | 0.00 | 7.12M | 771.25K |
| Depreciation & Amortization | 1.03M | 596.00K | 436.62K | 489.47K | 307.36K | 66.66K | 32.31K | 53.43K |
| EBITDA | -17.76M | -22.33M | -19.66M | -24.18M | -43.98M | -54.49M | -28.87M | -14.96M |
| EBITDA Ratio | -110.79% | -266.22% | -403.85% | -681.37% | -1,761.26% | -5,420.74% | -3,144.73% | -5,885.31% |
| Operating Income | -18.81M | -22.87M | -20.04M | -24.28M | -44.09M | -54.55M | -25.64M | -15.01M |
| Operating Income Ratio | -117.31% | -266.22% | -367.68% | -694.66% | -1,844.81% | -5,494.07% | -3,160.31% | -5,906.33% |
| Total Other Income/Expenses | -215.00K | 281.00K | 1.97M | -398.04K | -1.04M | -1.21M | -10.38M | -771.25K |
| Income Before Tax | -19.02M | -22.59M | -18.07M | -24.68M | -45.13M | -55.76M | -36.03M | -15.78M |
| Income Before Tax Ratio | -118.65% | -262.95% | -331.47% | -706.05% | -1,888.24% | -5,615.88% | -4,440.01% | -6,209.81% |
| Income Tax Expense | -186.00K | -431.00K | -851.20K | -1.17M | 18.00K | 2.43K | 6.88M | -44.15K |
| Net Income | -18.83M | -22.16M | -17.22M | -23.51M | -45.15M | -55.82M | -35.79M | -15.74M |
| Net Income Ratio | -117.49% | -257.94% | -315.86% | -672.55% | -1,889.00% | -5,621.66% | -4,410.88% | -6,192.44% |
| EPS | -3.42 | -4.69 | -4.36 | -9.04 | -23.05 | -28.61 | -1.36 | -1.57 |
| EPS Diluted | -3.42 | -4.69 | -4.36 | -9.04 | -23.05 | -28.61 | -1.36 | -1.57 |
| Weighted Avg Shares Out | 5.52M | 4.73M | 3.95M | 2.60M | 1.96M | 1.95M | 26.34M | 10.04M |
| Weighted Avg Shares Out (Dil) | 5.52M | 4.73M | 3.95M | 2.60M | 1.96M | 1.95M | 26.34M | 10.04M |
electroCore, Inc. Announces $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
ROCKAWAY, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to an institutional accredited investor an aggregate...
Wall Street Analysts See a 251.77% Upside in electroCore (ECOR): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 251.8% in electroCore (ECOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
Ecora Resources PLC Announces Transaction in Own Shares
LONDON, UNITED KINGDOM / ACCESSWIRE / May 20, 2024 / Ecora Resources PLC (LSE:ECOR)(TSX:ECOR) announces that on 20 May 2024, it purchased 200,000 ordinary shares of 2p each in the Company (the "Shares") on the London Stock Exchange through Peel...
Wall Street Analysts Think electroCore (ECOR) Could Surge 215.86%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 215.9% in electroCore (ECOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
electroCore, Inc. (ECOR) Q1 2024 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO Brian Posner - CFO Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Bruce Jackson - The Benchmark Company Swayampakula...
ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates
ElectroCore, Inc. (ECOR) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.24 per share a year ago.
electroCore Announces First Quarter 2024 Financial Results
Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023 Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
ROCKAWAY, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that on May 1, 2024, Donald Melnikoff joined electroCore as the Company's SVP, Engineering, Regulatory, and Compliance;...
electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024
ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of the market...
Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the results of its most recent Truvaga Plus consumer study conducted earlier this year. Based on a...
Source: https://incomestatements.info
Category: Stock Reports